Showing 1 - 10 of 2,820
Persistent link: https://www.econbiz.de/10011723117
Persistent link: https://www.econbiz.de/10011660160
Persistent link: https://www.econbiz.de/10011635704
This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that...
Persistent link: https://www.econbiz.de/10014195216
Persistent link: https://www.econbiz.de/10003931919
This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that...
Persistent link: https://www.econbiz.de/10009659550
opportunities available to pharmaceutical firms confronted with the loss of patent protection on their branded drug. The marketing …
Persistent link: https://www.econbiz.de/10013099957
Persistent link: https://www.econbiz.de/10011300287
Persistent link: https://www.econbiz.de/10011528777